Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroyasu Nishioka is active.

Publication


Featured researches published by Hiroyasu Nishioka.


Journal of Pharmacy and Pharmacology | 2000

Effects of ZNC-2381, a New Oral Compound, on Several Hepatic Injury Models and on Hepatocellular Apoptosis in Mice and Rats

Yoshihiko Itokazu; Yoshihide Segawa; Takeshi Omata; Naonori Inoue; Naoki Tsuzuike; Masaaki Nagasawa; Hiroyasu Nishioka; Tadashi Kobayashi; Yoshihisa Nakano; Takashi Kanda

The hepatoprotective effect of ZNC‐2381 (1‐(4‐aminophenyl) methyl‐3‐(3‐nitrophenyl)‐1,3‐dihydroimidazo[4,5‐b]pyridine‐2‐one), a novel 2‐one dihydroimidazopyridine derivative, has been evaluated in several experimental models of hepatic injury.


Pharmacology | 2001

Effects of a novel hepatoprotective drug, ZNC-2381, on fas-induced hepatocellular caspase-3 activity and apoptosis in mice.

Yoshihide Segawa; Naoki Tsuzuike; Yoshihiko Itokazu; Takeshi Omata; Naonori Inoue; Masaaki Nagasawa; Hiroyasu Nishioka; Yoshihisa Nakano; Tadashi Kobayashi; Takashi Kanda

We examined the effects of ZNC-2381 (1-(4-aminophenyl)methyl-3-(3-nitrophenyl)-1,3-dihydroimidazo[4,5-b] pyridine-2-one), a new oral hepatoprotective agent, on hepatocellular caspase-3 activity and apoptosis induced by anti-mouse Fas antibody (anti-Fas ab) in mice. Oral ZNC-2381, administered at doses of 10, 30 and 100 mg/kg 1 h before inducing hepatic injury with anti-Fas ab, dose-dependently inhibited the increase in serum alanine aminotransferase (s-ALT) activity 8 h after injection of anti-Fas ab. Increases in DNA fragmentation (nucleosome assay) and caspase-3 activity in the liver 2 h after injection of anti-Fas ab were also inhibited by ZNC-2381 in a dose-dependent manner. As shown by histopathological examination, ZNC-2381 dose-dependently inhibited the appearance of TUNEL-positive apoptotic cells in the liver. Moreover, in studies in vitro, ZNC-2381 (1– 100 µmol/l) concentration-dependently inhibited increases in DNA fragmentation and caspase-3 activity caused by anti-Fas ab in isolated mouse hepatocytes. N- Acetyl-Asp-Glu-Val-Asp aldehyde (Ac-DEVD-cho), a caspase-3-specific inhibitor, inhibited hepatocellular apoptosis caused by anti-Fas ab both in vivo and in vitro, as well as the increase in s-ALT activity in vivo. These results demonstrate that orally administered ZNC-2381 inhibits hepatocellular apoptosis induced by anti-Fas ab and presents the progression of hepatic injury. We propose that the mechanism of action of ZNC-2381 may involve blockade of the signal transduction pathway (caspase-3) of apoptosis mediated by anti-Fas ab.


Archive | 1996

Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds

Masaaki Nagasawa; Masakazu Murata; Hiroyasu Nishioka; Tadashi Kurimoto; Shigeru Ueki; Osamu Kitagawa


Archive | 1996

Aminothiazole derivative, medicament containing the same, and intermediate for preparation of said compound

Masaaki Nagasawa; Masakazu Murata; Hiroyasu Nishioka; Tadashi Kurimoto; Shigeru Ueki; Osamu Kitagawa


Synthesis | 2000

Regioselective Dealkylation of 2-Alkoxybenzoic Acid and Its Amide Derivatives with Aliphatic Amines

Hiroyasu Nishioka; Masaaki Nagasawa; Kiyoshi Yoshida


Archive | 1999

Condensed imidazole derivative and therapeutic agent for liver disease

Masaaki Nagasawa; Hiroyasu Nishioka; Takanori Suzuki; Yoshihide Segawa; Naoki Tsuzuike


Archive | 1998

Process for producing 2-hydroxybenzamide derivatives

Masaaki Nagasawa; Hiroyasu Nishioka; Takanori Suzuki; Eiichi Nagano; Katsuyuki Ishii; Ryu Nakao


Archive | 2001

Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients

Shigeru Ueki; Yuko Hori; Yugo Matsunaga; Masaaki Nagasawa; Hiroyasu Nishioka; Masakazu Murata


Archive | 2001

Pharmaceutical compositions containing aminothiazole derivatives for the treatment of the motor dysfunction of the large intestine

Hiroyasu Nishioka; Shigeru Ueki; Yuko Hori; Yugo Matsunaga; Masaaki Nagasawa; Masakazu Murata


Archive | 2001

Colonic motor dysfunction remedies

Shigeru Ueki; Yuko Hori; Yugo Matsunaga; Masaaki Nagasawa; Hiroyasu Nishioka; Masakazu Murata

Collaboration


Dive into the Hiroyasu Nishioka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge